AIMS / HYPOTHESIS
inflammatory signals and increase the synthesis of prostaglandins play a role during the development of diabetes. The prostaglandin D2 (PGD2) receptor, GPR44 / DP2, is highly expressed in human islets and insulin secretion pathway activation results impaired. GPR44 activation role in the function of small islands and the survival rate for chronic hyperglycaemic conditions are unknown. In this study, we investigated GPR44 GPR44 inhibition by using a selective antagonist (AZ8154) in humans the island both in vitro and in vivo in diabetic mice transplanted with human islets.
METHOD
human islets exposed to PGD2 or proinflammatory cytokines in vitro to determine the effect of GPR44 inhibition on the survival rate of the island. In addition, the molecular mechanism of inhibition of GPR44 investigated in human islets exposed to high concentrations of glucose (HG) and IL-1β.
To the in vivo from this study, human islets are transplanted under the kidney capsule of diabetic rats immunodeficiencies and treated with 6, 60 or 100 mg / kg per day antagonist of GPR44 from the day of transplantation until day 4 short-term (studies) or study days (term long-17) post transplant. IVGTT conducted in rats at 10 days 15 days post transplant. After the termination of the study, metabolic variables, human circulating proinflammatory cytokines, and hepatocyte growth factor (HGF) were analyzed in human islets transplanted.
RESULTS
PGD2 or proinflammatory cytokine-induced apoptosis in human islets, while GPR44 inhibition of reverse these effects. GPR44 inhibition of hate decreased insulin secretion induced by glucose-stimulated HG and IL-1β in human islets. It is accompanied by activation of glycogen synthase kinase-Akt signaling 3β together with the phosphorylation and inactivation of the forkhead box O-1 and upregulation of pancreatic and duodenal homeobox-1 and HGF.
GPR44 antagonist administration up to 17 days for the diabetic mice transplanted with human islets resulted in a marginal reduction in fasting blood glucose and lower glucose fluctuations during IVGTT. improved glucose regulation is supported by an increased level of human C-peptide compared to the vehicle group on day 4 and throughout the treatment period. GPR44 inhibition reduces plasma levels of TNF-α and growth-regulated oncogene-α / chemokine (C-X-C motif) ligand 1 and raise the level of HGF in human islets.
Inhibition of GPR44 in human islets have the potential to improve the functioning of small islands and the survival rate under pressure inflammation and hyperglycaemic. This may have implications for the survival rates were better than the island after transplantation.

1 Channel Control Pannexin endothelial inflammation by regulating intracellular calcium.
The proinflammatory cytokine IL-1β is a significant risk factor in cardiovascular disease that can be targeted to reduce major cardiovascular events. expression and release of IL-1β is tightly controlled by changes in intracellular Ca2 + ([Ca2 +] i), which has been associated with the release of ATP and purinergic signaling. However, the mechanisms that regulate these changes have not been identified.
Interleukin 8 (IL8) Antibody |
|||
20-abx270201 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx173191 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx177199 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx177201 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
abx216289-100ug | Abbexa | 100 ug | EUR 526.8 |
Interleukin 8 (IL8) Antibody |
|||
abx020956-05mg | Abbexa | 0.5 mg | EUR 1296 |
Interleukin 8 (IL8) Antibody |
|||
abx018002-100ug | Abbexa | 100 ug | EUR 410.4 |
Interleukin 8 (IL8) Antibody |
|||
abx036426-100ug | Abbexa | 100 ug | EUR 469.2 |
Interleukin 8 (IL8) Antibody |
|||
20-abx100960 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100961 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100962 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100963 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100964 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100965 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100966 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100967 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100969 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100970 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100971 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx100972 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx131832 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx131833 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx131834 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx131835 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx131836 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx131837 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx131838 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx131839 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx131840 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody |
|||
20-abx009111 | Abbexa |
|
|
Dog Interleukin-8 (IL8) |
|||
1-CSB-YP011671DO | Cusabio |
|
|
Description: Recombinant Dog Interleukin-8(IL8) expressed in Yeast |
Dog Interleukin-8 (IL8) |
|||
1-CSB-EP011671DO | Cusabio |
|
|
Description: Recombinant Dog Interleukin-8(IL8) expressed in E.coli |
Dog Interleukin-8 (IL8) |
|||
1-CSB-MP011671DO | Cusabio |
|
|
Description: Recombinant Dog Interleukin-8(IL8) expressed in Mammalian cell |
Active Interleukin 8 (IL8) |
|||
4-APA080Hu01 | Cloud-Clone |
|
|
Description: Recombinant Human Interleukin 8 expressed in: Available from E.coli, Yeast, Baculovirus and Mammalian cells |
Sheep Interleukin-8 (IL8) |
|||
1-CSB-EP011671SH | Cusabio |
|
|
Description: Recombinant Sheep Interleukin-8(IL8) expressed in E.coli |
Active Interleukin 8 (IL8) |
|||
RPU59242-100ug | Biomatik Corporation | 100ug | EUR 1140.2 |
Active Interleukin 8 (IL8) |
|||
RPU59242-1mg | Biomatik Corporation | 1mg | EUR 5054.4 |
Active Interleukin 8 (IL8) |
|||
RPU59242-50ug | Biomatik Corporation | 50ug | EUR 760.3 |
Active Interleukin 8 (IL8) |
|||
RPU55475-100ug | Biomatik Corporation | 100ug | EUR 453.2 |
Active Interleukin 8 (IL8) |
|||
RPU55475-1mg | Biomatik Corporation | 1mg | EUR 2009.8 |
Active Interleukin 8 (IL8) |
|||
RPU55475-50ug | Biomatik Corporation | 50ug | EUR 364.1 |
Interleukin 8 (IL8) Antibody (PE) |
|||
20-abx270865 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (PE) |
|||
20-abx270914 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (PE) |
|||
20-abx270962 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (PE) |
|||
20-abx270963 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (PE) |
|||
20-abx274631 | Abbexa |
|
|
Eukaryotic Interleukin 8 (IL8) |
|||
4-EPA080Bo61 | Cloud-Clone |
|
|
Description: Recombinant Bovine Interleukin 8 expressed in: 293F cell |
Eukaryotic Interleukin 8 (IL8) |
|||
RPU52379-100ug | Biomatik Corporation | 100ug | EUR 517 |
Eukaryotic Interleukin 8 (IL8) |
|||
RPU52379-1mg | Biomatik Corporation | 1mg | EUR 2293.2 |
Eukaryotic Interleukin 8 (IL8) |
|||
RPU52379-50ug | Biomatik Corporation | 50ug | EUR 415.8 |
Interleukin 8 (IL8) Antibody (APC) |
|||
20-abx270633 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (APC) |
|||
20-abx270682 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (APC) |
|||
20-abx270730 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (APC) |
|||
20-abx270731 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (APC) |
|||
20-abx177200 | Abbexa |
|
|
Recombinant Interleukin 8 (IL8) |
|||
4-RPA080Ca01 | Cloud-Clone |
|
|
Description: Recombinant Dog Interleukin 8 expressed in: E.coli |
Recombinant Interleukin 8 (IL8) |
|||
4-RPA080Eq01 | Cloud-Clone |
|
|
Description: Recombinant Horse Interleukin 8 expressed in: E.coli |
Recombinant Interleukin 8 (IL8) |
|||
4-RPA080Ga01 | Cloud-Clone |
|
|
Description: Recombinant Chicken Interleukin 8 expressed in: E.coli |
Recombinant Interleukin 8 (IL8) |
|||
4-RPA080Gu01 | Cloud-Clone |
|
|
Description: Recombinant Guinea pig Interleukin 8 expressed in: E.coli |
Recombinant Interleukin 8 (IL8) |
|||
4-RPA080Hu01 | Cloud-Clone |
|
|
Description: Recombinant Human Interleukin 8 expressed in: E.coli |
Recombinant Interleukin 8 (IL8) |
|||
4-RPA080Ov01 | Cloud-Clone |
|
|
Description: Recombinant Sheep Interleukin 8 expressed in: E.coli |
Recombinant Interleukin 8 (IL8) |
|||
4-RPA080Po01 | Cloud-Clone |
|
|
Description: Recombinant Pig Interleukin 8 expressed in: E.coli |
Recombinant Interleukin 8 (IL8) |
|||
4-RPA080Rb01 | Cloud-Clone |
|
|
Description: Recombinant Rabbit Interleukin 8 expressed in: E.coli |
Recombinant Interleukin 8 (IL8) |
|||
4-RPA080Si01 | Cloud-Clone |
|
|
Description: Recombinant Simian Interleukin 8 expressed in: E.coli |
Recombinant Interleukin 8 (IL8) |
|||
RPU42325-100ug | Biomatik Corporation | 100ug | EUR 468.6 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42325-1mg | Biomatik Corporation | 1mg | EUR 2074.8 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42325-50ug | Biomatik Corporation | 50ug | EUR 376.2 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42326-100ug | Biomatik Corporation | 100ug | EUR 554.4 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42326-1mg | Biomatik Corporation | 1mg | EUR 2457 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42326-50ug | Biomatik Corporation | 50ug | EUR 445.5 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42327-100ug | Biomatik Corporation | 100ug | EUR 591.8 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42327-1mg | Biomatik Corporation | 1mg | EUR 2620.8 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42327-50ug | Biomatik Corporation | 50ug | EUR 475.2 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42328-100ug | Biomatik Corporation | 100ug | EUR 517 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42328-1mg | Biomatik Corporation | 1mg | EUR 2293.2 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42328-50ug | Biomatik Corporation | 50ug | EUR 415.8 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42329-100ug | Biomatik Corporation | 100ug | EUR 369.6 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42329-1mg | Biomatik Corporation | 1mg | EUR 1638 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42329-50ug | Biomatik Corporation | 50ug | EUR 297 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42330-100ug | Biomatik Corporation | 100ug | EUR 591.8 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42330-1mg | Biomatik Corporation | 1mg | EUR 2620.8 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42330-50ug | Biomatik Corporation | 50ug | EUR 475.2 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42331-100ug | Biomatik Corporation | 100ug | EUR 591.8 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42331-1mg | Biomatik Corporation | 1mg | EUR 2620.8 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42331-50ug | Biomatik Corporation | 50ug | EUR 475.2 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42332-100ug | Biomatik Corporation | 100ug | EUR 591.8 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42332-1mg | Biomatik Corporation | 1mg | EUR 2620.8 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42332-50ug | Biomatik Corporation | 50ug | EUR 475.2 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42333-100ug | Biomatik Corporation | 100ug | EUR 616 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42333-1mg | Biomatik Corporation | 1mg | EUR 2730 |
Recombinant Interleukin 8 (IL8) |
|||
RPU42333-50ug | Biomatik Corporation | 50ug | EUR 495 |
Recombinant Interleukin 8 (IL8) |
|||
RPU58416-100ug | Biomatik Corporation | 100ug | EUR 551.1 |
Recombinant Interleukin 8 (IL8) |
|||
RPU58416-1mg | Biomatik Corporation | 1mg | EUR 2558.4 |
Recombinant Interleukin 8 (IL8) |
|||
RPU58416-50ug | Biomatik Corporation | 50ug | EUR 428.5 |
Recombinant Interleukin 8 (IL8) |
|||
RPU58417-100ug | Biomatik Corporation | 100ug | EUR 551.1 |
Recombinant Interleukin 8 (IL8) |
|||
RPU58417-1mg | Biomatik Corporation | 1mg | EUR 2558.4 |
Recombinant Interleukin 8 (IL8) |
|||
RPU58417-50ug | Biomatik Corporation | 50ug | EUR 428.5 |
Interleukin 8 (IL8) Antibody (FITC) |
|||
20-abx270401 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (FITC) |
|||
20-abx270450 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (FITC) |
|||
20-abx270498 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (FITC) |
|||
20-abx270499 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (FITC) |
|||
20-abx271013 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody Pair |
|||
abx117314-1pair5x96wellplates | Abbexa | 1 pair (5x96 well plates) | EUR 1212 |
Interleukin 8 (IL8) Antibody Pair |
|||
20-abx370066 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody Pair |
|||
20-abx370068 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody Pair |
|||
20-abx370095 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody Pair |
|||
20-abx370128 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody Pair |
|||
20-abx370248 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody Pair |
|||
20-abx370249 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody Pair |
|||
20-abx370251 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody Pair |
|||
20-abx370256 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody Pair |
|||
20-abx370625 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody Pair |
|||
20-abx370655 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (FITC) |
|||
20-abx273525 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (FITC) |
|||
20-abx273530 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (FITC) |
|||
20-abx273545 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (FITC) |
|||
20-abx274200 | Abbexa |
|
|
Interleukin 8 (IL8) Antibody (FITC) |
|||
20-abx273851 | Abbexa |
|
|
Interleukin 8 / IL8 (CXCL8) Antibody |
|||
20-abx317929 | Abbexa |
|
|
Interleukin 8 / IL8 (CXCL8) Antibody |
|||
abx200558-100ug | Abbexa | 100 ug | EUR 543.6 |
Interleukin 8 / IL8 (CXCL8) Antibody |
|||
20-abx210112 | Abbexa |
|
|
Interleukin 8 / IL8 (CXCL8) Antibody |
|||
20-abx109944 | Abbexa |
|
|
Interleukin 8 / IL8 (CXCL8) Antibody |
|||
20-abx110542 | Abbexa |
|
|
Interleukin 8 / IL8 (CXCL8) Antibody |
|||
20-abx110581 | Abbexa |
|
|
Interleukin 8 / IL8 (CXCL8) Antibody |
|||
20-abx113257 | Abbexa |
|
|
Interleukin 8 / IL8 (CXCL8) Antibody |
|||
abx034024-400ul | Abbexa | 400 ul | EUR 627.6 |
Interleukin 8 / IL8 (CXCL8) Antibody |
|||
abx034024-80l | Abbexa | 80 µl | EUR 343.2 |
Interleukin 8 / IL8 (CXCL8) Antibody |
|||
20-abx100968 | Abbexa |
|
|
The pannexin 1 (Panx1) channel has been canonically been involved in the ATP release, particularly during inflammation. We checked Panx1 in human umbilical vein endothelial cells after treatment with proinflammatory cytokines TNF-α. Analysis by the whole transcriptome sequencing and immunoblot Panx1 identified a dramatic increase in mRNA and protein expression were regulated by NF-kB-dependent.